Published in Medical Letter on the CDC and FDA, November 14th, 2004
This clinical trial will be evaluating efficacy, safety, and tolerability of a 28-day course of daily E1-I.N.T. treatments with a 6-month follow-up. E1- I.N.T. is a short course combination therapy aimed at stimulating the regeneration of the body's insulin-producing cells.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.